| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | BIBW2992 | FIMM | pan-cancer | AAC | -0.2 | 0.2 |